{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096172","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.175229+00:00","generated_at":"2026-05-31T09:45:08.439901+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Korro Bio Q2 net loss $21.8M; cash $187.8M; KRRO-110 FIH filing on track","bullets":["Net loss of $21.8M for Q2 2024, up from $17.6M in Q2 2023, driven by higher R&D and G&A costs.","Cash, equivalents & marketable securities total $187.8M as of June 30, 2024; runway into H2 2026.","Regulatory filing for KRRO-110 first-in-human trial in AATD expected in H2 2024.","Preclinical data showed >70% M-AAT protein in circulation with ~60% sustained editing efficiency.","Completed $70M private placement in April 2024 to support pipeline development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096172","json":"https://secwatch.observer/filing/0000950170-24-096172.json","markdown":"https://secwatch.observer/filing/0000950170-24-096172.md","text":"https://secwatch.observer/filing/0000950170-24-096172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024096172/0000950170-24-096172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024096172/krro-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:45:08.439901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}